Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Sells 12,500 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CEO Samuel Kintz sold 12,500 shares of the stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $20.83, for a total transaction of $260,375.00. Following the transaction, the chief executive officer now owns 990,392 shares of the company's stock, valued at approximately $20,629,865.36. The trade was a 1.25 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Enliven Therapeutics Price Performance

NASDAQ:ELVN traded up $0.16 on Friday, reaching $21.08. 407,065 shares of the company's stock were exchanged, compared to its average volume of 269,341. The stock has a fifty day simple moving average of $21.31 and a 200-day simple moving average of $23.77. Enliven Therapeutics, Inc. has a 52 week low of $15.96 and a 52 week high of $30.03. The firm has a market cap of $1.03 billion, a price-to-earnings ratio of -11.09 and a beta of 1.04.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its quarterly earnings data on Thursday, March 13th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.07. The business had revenue of $0.03 million during the quarter. As a group, sell-side analysts predict that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Remove Ads

Hedge Funds Weigh In On Enliven Therapeutics

Hedge funds have recently made changes to their positions in the stock. Barclays PLC lifted its holdings in Enliven Therapeutics by 295.8% during the 3rd quarter. Barclays PLC now owns 56,217 shares of the company's stock worth $1,435,000 after purchasing an additional 42,012 shares in the last quarter. First Turn Management LLC lifted its holdings in shares of Enliven Therapeutics by 29.5% in the third quarter. First Turn Management LLC now owns 535,092 shares of the company's stock worth $13,666,000 after buying an additional 121,849 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Enliven Therapeutics by 9.9% in the third quarter. Geode Capital Management LLC now owns 750,208 shares of the company's stock valued at $19,164,000 after acquiring an additional 67,813 shares during the period. Ally Bridge Group NY LLC bought a new stake in Enliven Therapeutics during the 3rd quarter worth approximately $5,998,000. Finally, Patient Square Capital LP bought a new stake in Enliven Therapeutics during the 3rd quarter worth approximately $2,313,000. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ELVN has been the subject of a number of research reports. HC Wainwright increased their target price on shares of Enliven Therapeutics from $37.00 to $39.00 and gave the company a "buy" rating in a research report on Friday. BTIG Research began coverage on Enliven Therapeutics in a report on Friday, December 13th. They set a "buy" rating and a $42.00 price objective for the company. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Enliven Therapeutics currently has a consensus rating of "Buy" and an average price target of $38.75.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.